Last reviewed · How we verify
DEXBROMPHENIRAMINE MALEATE
DEXBROMPHENIRAMINE MALEATE is a drug. It is currently FDA-approved (first approved 1963) for Hay Fever Symptoms Relief, Upper Respiratory Allergies Symptoms Relief.
Dexbrompheniramine Maleate is a marketed antihistamine primarily indicated for the relief of hay fever symptoms. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue stability. The primary risk is the loss of patent protection in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | DEXBROMPHENIRAMINE MALEATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1963 |
Approved indications
- Hay Fever Symptoms Relief
- Upper Respiratory Allergies Symptoms Relief
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DEXBROMPHENIRAMINE MALEATE CI brief — competitive landscape report
- DEXBROMPHENIRAMINE MALEATE updates RSS · CI watch RSS